公开(公告)号：US20220249527A1

公开(公告)日：2022-08-11

申请号：US17728189

申请日：2022-04-25

Applicant: ABBOTT LABORATORIES

Inventor： Steven R. DAVIS ,  Rachael BUCK ,  Geralyn O. DUSKA-MCEWEN

IPC: A61K31/702 ,  A61K31/7016

Abstract: Disclosed are methods of reducing the incidence of oxidative stress in infants, toddlers, and children using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective at reducing inflammation and the incidence of inflammatory diseases.

公开(公告)号：US20210113630A1

公开(公告)日：2021-04-22

申请号：US16625429

申请日：2018-06-21

Applicant: ABBOTT LABORATORIES

Inventor： Alejandro Perez BARRANCO ,  Maria Gonzalez RAMIREZ ,  Rachael BUCK ,  Enrique Hernandez VAZQUEZ

IPC: A61K35/747 ,  A61K31/702 ,  A61K31/355 ,  A61K31/047 ,  A61K35/745 ,  A61K35/20 ,  A61K9/107 ,  A61K47/46 ,  A61K47/44 ,  A61K47/26 ,  A61K47/24 ,  A61K47/02 ,  A61K47/22 ,  A61K47/42 ,  A61K47/36 ,  A61K47/12 ,  A61K31/07 ,  A61K31/122 ,  A61K31/593 ,  A61K31/714 ,  A61K31/015 ,  A61K31/519 ,  A61K31/4188 ,  A61K31/525 ,  A61K31/4415 ,  A61K47/14 ,  A61K31/405 ,  A61K31/205 ,  A61K31/14 ,  A61K31/145 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/7072 ,  A61K33/06 ,  A61K33/30 ,  A61K33/26 ,  A61P1/14 ,  A23L33/00 ,  A23L33/125 ,  A23L33/15 ,  A23L33/135

Abstract: Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US20230293561A1

公开(公告)日：2023-09-21

申请号：US18006802

申请日：2021-07-26

Applicant: ABBOTT LABORATORIES

Inventor： Manuel MANZANO ,  Enrique HERNANDEZ ,  José María LÓPEZ PEDROSA ,  Ricardo RUEDA CABRERA ,  Rachael BUCK

IPC: A61K31/702 ,  A61K45/06 ,  A61P3/06 ,  A61K9/00 ,  A61P1/16

CPC classification number: A61K31/702 ,  A61K45/06 ,  A61P3/06 ,  A61K9/0053 ,  A61P1/16

Abstract: A method of reducing or delaying the onset of fatty liver disease in a subject comprises enterally administering at least one human milk oligosaccharide (HMO) to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the at least one HMO is administered in an amount effective to reduce de novo lipogenesis in the subject. The at least one HMO can be administered to the subject directly or in a nutritional composition.

公开(公告)号：US20230074237A1

公开(公告)日：2023-03-09

申请号：US17682051

申请日：2022-02-28

Applicant: ABBOTT LABORATORIES

Inventor： Alejandro Perez Barranco ,  Maria Ramirez Gonzalez ,  Rachael BUCK ,  Enrique Vazquez Hernandez

IPC: A61K35/747 ,  A23L33/125 ,  A23L33/15 ,  A23L33/135 ,  A23L33/00 ,  A61P1/14 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46

Abstract: Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US20220395542A1

公开(公告)日：2022-12-15

申请号：US17776792

申请日：2020-11-19

Applicant: ABBOTT LABORATORIES

Inventor： Enrique VÁZQUEZ HERNÁNDEZ ,  Rachael BUCK ,  JoMay CHOW ,  Karen GOEHRING

IPC: A61K35/745 ,  A61K31/702 ,  A61K47/36 ,  A61K35/747 ,  A61K35/744 ,  A61K35/741 ,  A61K36/064 ,  A61P31/04

Abstract: A nutritional composition comprises fucosylated human milk oligosaccharide and/or sialylated human milk oligosaccha-ride, non-digestible, fermentable polysaccharide, and Bifidobacterium. The nutritional composition is free of short-chain fructooligosac-charide having at least about 50% of molecules with a degree of polymerization of less than about 5. A method of treating a subject at risk of developing a Clostridium difficile infection or a subject having a Clostridium difficile infection comprises administering such a nutritional composition.